The purpose of this study is to evaluate the tolerability and benefit of IQP-AS-121 on reducing fatigue and tiredness and to improve mental alertness.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
analyze & realize GmbH
Berlin, Germany
Change in VAS-F parameter
Compared between timepoints week 6 versus baseline \- To assess fatigue and energy with 18 items which possesses two subscales: fatigue (13 items) and energy (5 items).
Time frame: 6 weeks
Change in Bond & Lader VAS parameter
Compared between timepoints week 6 versus baseline \- To assess alertness, contentedness and calmness
Time frame: 6 weeks
Change in Number Connection Test
Compared between timepoints week 6 versus baseline \- To assess visuo-spatial orientation and cognitive processing speed.
Time frame: 6 weeks
Change in FAIR-2
Compared between timepoints week 6 versus baseline \- To measure attention as an ability to concentrate
Time frame: 6 weeks
Change in SF-12 parameter
Compared between timepoints week 6 versus baseline \- To measure the overall health status of a subject
Time frame: 6 weeks
Change in PSQ20 parameter
Compared between timepoints week 6 versus baseline \- Contained 30 items as an instrument to assess subjectively experienced stress
Time frame: 6 weeks
Change in POMS-35 parameters
Compared between timepoints week 6 versus baseline \- The POMS-65 comprises 65 adjectives, separated into 6 subscales: 1) depression-dejection, 2) tension-anxiety, 3) anger-hostility, 4) confusion bewilderment, 5) fatigue-inertia and 6) vigour-activity.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 weeks
Global evaluation of benefit
Assessed by the subjects and investigator at the end of study \- To evaluate benefit of IP
Time frame: 6 weeks
Adverse events
Assessed throughout the study
Time frame: 6 weeks
Global evaluation of tolerability
Assessed by the subjects and investigator at the end of study
Time frame: 6 weeks